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Summary We have compared the expression of somatostatin receptor(sstr) subtypes with the outcome of somatostatin receptorscintigraphy
and the effect of somatostatin receptor activation in patients with disseminated carcinoid tumours. Tumour tissues from nine patients with
midgut carcinoids (ileal) and three patients with foregut carcinoids (gastric, thymic) were analysed using Northern blotting. Expression of
somatostatin receptors was demonstrated in all tumours (12 out of 12), with all five receptor subtypes present in 9 out of 12 tumours.
Somatostatin receptor scintigraphy using [1111n]DTPA-D-Phe1-octreotide visualized tumours in all patients (12 out of 12). The "'in activity
concentrations in tumour tissue (T) and blood (B) were determined in three tumours 1-7 days after injection of the radionuclide. The T/B 1111n
activity concentration ratios ranged between 32 and 651. Clinically, treatment with the long-acting somatostatin analogue octreotide resulted
in marked symptom relief accompanied by a significant reduction in tumour markers, for example urinary-5-HIAA levels (28-71% reduction).
Incubation of midgut carcinoid tumours in primary culture with octreotide (10gM) resulted in a reduction in spontaneously secreted serotonin
(45-71% reduction) and 5-HIAA (41-94% reduction). The results demonstrate that carcinoid tumours possess multiple somatostatin receptor
subtypes and that somatostatin analogues such as octreotide, which preferentially bind to somatostatin receptor subtype 2 and 5, can be
used in the diagnosis and medical treatment of these tumours. In the future, novel somatostatin analogues with subtype specific receptor
profiles may prove to be of value for individualizing the treatment of disseminated carcinoid tumour disease.
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Binding studies and autoradiography using radiolabelled somato-
statin-14 or -28, or its analogues, have shown that 80-90% of all
neuroendocrine tumours of the gastrointestinal tract possess high
numbers of somatostatin receptors (Reubi et al, 1987; 1990).
Activation of these receptors inhibits the secretion of tumour
products and may also inhibit tumour growth (Kvols et al, 1986;
Gorden et al, 1989; Wangberg etal, 1991; Saltz et al, 1993; Arnold
et al, 1996). The use of long-acting somatostatin analogues, for
example octreotide, has become a well-established medical treat-
ment strategy with excellent control ofpatient symptoms (Gorden
et al, 1989). Scintigraphy using [ll1n]DTPA-D-Phel-octreotide has
become a valuable diagnostic tool to determine the extent of
tumour disease and for planning surgical treatment (Bakker et al,
1991; Ahlman et al, 1994).
Five different subtypes of human somatostatin receptors (sstr)
have been cloned and functionally characterized. Each receptor is
encoded by a unique gene, located on separate chromosomes in
man (Raulf et al, 1994). The somatostatin receptors belong to the
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superfamily of G-protein-coupled receptors with seven putative
membrane-spanning domains. The physiological or pathophysio-
logical roles of each receptor subtype have been difficult to estab-
lish because of the lack of subtype-specific receptor agonists or
antagonists. However, the pharmacology of the cloned somato-
statin receptor subtypes have been studied in expression systems
using non-neuroendocrine cells, demonstrating preferential binding
of octreotide tor sstr2 and 5 (Bruns et al, 1994; Patel and Srikant,
1994). Based on binding studies of the cloned receptors, sstr2 has
been suggested to be the main target for octreotide and a prerequi-
site for tumour imaging. This assumption has been supported by
studies comparing octreotide scintigraphy with the expression of
sstr subtypes in gastroenteropancreatic endocrine tumours (Kubota
et al, 1994; John et al, 1996). However, in these studies only small
numbers of each tumour type were analysed by reverse transcrip-
tase polymerase chain reaction (RT-PCR) and correlated with
octreotide scintigraphy or somatostatin autoradiography.
In the present study, we have for the first time examined the
expression ofsstr subtypes in a series ofgastrointestinal carcinoids
using subtype-specific riboprobes and high-stringency Northern
analysis. The results were compared with the findings obtained
at ["'In]DTPA-D-Phe'-octreotide scintigraphy. Furthermore, we
studied the secretory responses ofindividual tumours to octreotide
in primary tumour cell cultures and in the clinical situation.
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Table 1 Clinical characteristics of patients with carcinoid tumours
Primary tumour
U-5HIAA before therapy
Case Age Sex Site Type Sites of metastases (,umol per24 h)
1 54 F Ileum MC N1lMV1COS1 780
2 74 F Ileum MC N1M2C1SO 870
3 71 M Ileum MC N1IM2COSO 140
4 66 F Ileum MC NlMOC1SO 105
5 67 F Ileum MC NlMlCOSO 1679
6 63 F Ileum MC N1M2C1SO 659
7 46 F Ileum MC N1M2COSO 2100
8 62 F Ileum MC N1M2C1SO 200
9 76 F Ileum MC N1M2COSO 310
10 70 F Stomach FC N1M2COSO 23
11 63 F Thymus FC NiMOCOSO 220
12 50 M Thymus FC NiMOCOSO 76
F, female; M, male; MC, midgut carcinoid; FC, foregut carcinoid; U-5HIAA, urinary excretion of 5-hydroxyindole acetic acid, reference
value < 50 gmol per 24 h. Tumour status: NO/i, regional lymph node metastases absent/present; MOt1/2, hepatic metastases
absent/unilobar/bilobar; CO/i, peritoneal metastases absent/present; SO/i, skeletal metastases absent/present.
MATERIAL AND METHODS
Tumour material and clinical histories
Nine patients with midgut carcinoids (ileal) and three patients with
foregut carcinoids (one gastric, two thymic) were studied (Table 1).
All patients had disseminated disease with metastatic tumour
growth in regional lymph nodes and/or liver. All patients except
one (case 11, thymic carcinoid) had hormonal symptoms, for
example facial flush, diarrhoea, bronchoconstriction, with
elevated levels of 5-HIAA (the main serotonin metabolite) or
MeImAA (the main histamine metabolite) in the urine. All symp-
tomatic patients responded clinically to octreotide treatment with
alleviation of hormonal symptoms. Tumour tissues for the deter-
mination of "IIn activity concentration (case 1, 7 and 10) were
obtained from primary tumours, lymph node and liver metastases.
Tissues for the study of sstr expression and cell culture etperi-
ments were obtained from either lymph node or liver metastases
except for two patients, in whom tissue from the primary tumour
was harvested (cases 11 and 12). Primary tumours and metastases
were evaluated histologically and classified according to site and
staining properties (argyrophil and argentaffin reactions).
Somatostatin receptor scintigraphy
Each patient received 10-20 jg of [l'In]DTPA-D-Phe'-octreotide
by i.v. injection 1-7 days before surgery. The administered activity
was 190-300 MBq. A gamma-camera (General Electric 400 AC/T)
equipped with a medium-energy parallel-hole collimatorconnected
to a GE STARCAM computer system was used. Data acquisitions
were performed in a 128 x 128 matrix, using a dual window setting
of 173 and 247 keV (20% window width). Static anterior and
posterior images from the base ofthe skull to the pelvis were taken
in all patients. The static images were acquired for 10 min or until
500 kcounts were collected. Single photon emission computerized
tomography (SPECT) was carried out 48 h after injection using a
3600 rotation in 64 steps with 30 s per step. Prefiltration was
performed using a Hanning filter (cut-off frequency of 0.7 cm-')
and transaxial slices were reconstructed with a ramp filter.
Measurement of "11in activity in tissue samples
Before histopathological examination, surgical specimens from
three patients (cases 1, 7 and 10) together with blood samples
drawn during surgery were weighed and the "'In activity
measured in a calibrated gamma-counter equipped with a sodium
iodide well crystal (diameter 7.6 cm, length 7.6 cm, Harshaw,
Holland). The hole in the crystal had a diameter of 3 cm and a
depth of 6 cm. A single-channel pulse-height analyser (Elscint,
Haifa, Israel) was used. Corrections were made for background
activity and radioactive decay. The activity concentrations per
gram of tumour tissue and blood were determined and the tumour
to blood I''In activity concentration ratio (T/B) was calculated.
Northern analysis
Tumour biopsies obtained at surgery were immediately frozen in
liquid nitrogen and stored at-80°C until extraction ofRNA. Total
RNA was prepared by acid guanidinum thiocyanate-phenol-
chloroform extraction (Chomczynski and Sacchi, 1987). Samples
of RNA (20 ig per sample) were heat denatured and electro-
phoresed in a 1% agarose gel with 2.2 M formaldehyde, 1 mM
EDTA, 5 mM sodium acetate and 20 mm MOPS (pH 7.0) as
running buffer. RNA was transferred to positively charged nylon
membranes (Boehringer Mannheim, Mannheim, Germany)
using a vacuum transfer system and cross-linked to membranes
using UV light (Stratalinker, Stratagene, La Jolla, CA, USA).
Membranes were hybridized in rotating flasks at 65°C.
Prehybridization was carried out for 2-4 h in a solution of 5 x
sodium saline citrate (SSC), 50% formamide, 0.1% N-lauroylsav-
cosine, 0.02% SDS and 5% blocking reagent (Boehringer)
followed by hybridization overnight with 32P-labelled antisense
RNA probes added to the prehybridization solution. Stringency
washing was performed at 65°C using 0.1 x SSC (15 min x 3). 32p_
labelled RNA probes for the five sstr subtypes were generated
from linearized plasmids using SP6 or T7 RNA polymerase.
Labelled sense RNA probe served as non-specific controls.
Specific labelling was detected by 1-4 days' exposure on an
imaging plate followed by reading in a PhosphorImager
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(Molecular Dynamics, Sunnyvale, CA, USA). Transcript sizes
were estimated using a 0.24-9.5 kb RNA Ladder (Gibco BRL,
Gaithersburg, MD, USA). To determine the amount ofRNA cross-
linked to the membranes, membranes were reprobed with a 1.0-kb
human G3PDH cRNA probe (Cat. no. 9805; Clontech, Palo Alto,
CA, USA).
Probes
sstrl
A 1.126-bp fragment of human sstrl (Yamada et al, 1992) corre-
sponding to nucleotides 352-1478 was generated using PCR from
genomic DNA and subcloned into a pGEM-T vector (Promega).
The identity ofthe cloned fragment was confirmed by sequencing.
cRNA probes were generated from plasmids linearized with PstI
using T7 RNA polymerase.
sstr2
A 1.7-kb BamHI-HindIII fragment of human sstr2 (Yamada et al,
1992) cloned into a pGEM-3Z vector (Promega) was generously
supplied by Graeme I Bell, University of Chicago, IL, USA. The
identity of the fragment was confirmed by sequencing. cRNA
probes were generated from plasmids linearized with BamHI using
SP6 RNA polymerase.
sstr3
A 1.9-kb Ncol-HindIll fragment of human sstr3 (Yamada et al,
1992) in pCMV6c was generously supplied by Graeme I Bell,
University ofChicago, IL, USA. The fragment was subcloned into
a pGEM-3Z vector. The identity of the subcloned fragment was
confirmed by sequencing. cRNA probes were generated from
plasmids linearized with KpnI using SP6 RNA polymerase.
sstr4
A 2.0-kb NaeI-XbaI fragment of human sstr4 (Raulf et al, 1994)
cloned into pBluescript II SK+ was generously supplied by
Friedrich Raulf, Preclinical Research, Sandoz, Basle, Switzerland.
The identity ofthe fragment was confirmed by sequencing. cRNA
probes were generated from plasmids linearized with XbaI using
T7 RNA polymerase.
sstr5
A 1.6-kb EcoRI-SalIl fragment of human sstr5 (Yamada et al,
1993) cloned into pCMV6c was generously supplied by Susumo
Seino, Chiba University School ofMedicine, Japan. The fragment
was subcloned into a pGEM-3Z vector. The identity of the
subcloned fragment was confirmed by sequencing. cRNA probes
were generated from plasmids linearized with EcoRI using SP6
RNA polymerase.
Cell cultures
Primary cultures from six carcinoid tumours were prepared as
described previously (Ahlman et al, 1988). Tumour biopsies
obtained at surgery were minced into 1-2 mm pieces and incu-
bated in RPMI-1640 medium (Gibco-BRL, Gaithersburg, MD,
USA) with 0.2% collagenase (type I, Sigma, St Louis, MO, USA)
and 0.004% DNAase (type I, Sigma). Incubation was carried out at
37°C for 60 min with continuous oxygenation. Cell suspensions
were filtered, centrifuged at 175 g for 5 min, washed and
centrifuged twice in RPMI-1640 solution to remove collagenase.
Aliquots (1 ml) of the final tumour cell suspensions were seeded
onto collagen-coated (collagen type I, Collaborative Research,
Lexington, MA, USA) tissue culture plates (Nunc, Naperville, IL,
USA). Seeding densities varied slightly between different experi-
ments, but were always between 105 and 106 cells per well. RPMI-
1640 culture medium was supplemented with 4% heat-inactivated
fetal calf serum, L-glutamine (5 mM), transferrin (5 gg ml-'),
insulin (5 j ml-1), penicillin (200 IU ml-') and streptomycin
(200gg ml-'), and incubated at 37°C in a 90% humidified atmos-
phere. Culture media were changed every 3 or 4 days. After 2-4
weeks in primary culture, tumour cells were incubated with
octreotide at a concentration of 10gM for 7-12 days. Culture
media were analysed for 5-HT and 5-HIAA. The human pancre-
atic carcinoid cell line BON (Evers et al, 1991) was maintained in
cell culture under identical conditions and harvested for extraction
of RNA and Northern analysis. Octreotide treatment (10 jM) was
carried out for 4 days.
Determination of 5-HT and 5-HIAA
To determine 5-HT and 5-HIAA, aliquots (20g1) of culture
medium were injected onto the column of a reverse-phase HPLC
system with electrochemical detection. Standard curves were
made by injecting standard solutions of 5-HT (5-HT creatinine
sulphate, Sigma) and 5-HIAA in 20 pl of 0.1 M perchloric acid
(Westberg et al, 1997).
Statistical methods
For statistical analysis oftissue culture experiments unpaired t-test
(two-tailed) was used. Values are given as means ± s.e.m.
RESULTS
Somatostatin receptor scintigraphy and T/B 1111n
activity concentration ratios
All patients (n = 12) had positive tumour imaging with octreotide
scintigraphy at the site ofbiopsy. I"I In activity concentrations were
determined in the primary tumour and metastases of two midgut
carcinoids (cases 1 and 7) and of one foregut carcinoid (case 10).
The T/B ratios were very high in the tumour tissues ranging from
32 to 651 (Table 2). These values seemed to be lower for the
primaries (71, 35, 153, cases 10, 7 and 1 respectively) and lymph
node metastases (32, 200, case 10; and 39, case 7) than for the
liver metastases (100, 150, 150, 180, 210, case 10; 151, case 7; and
402, 469, 651, case 1).
Somatostatin receptor subtypes
Tumour tissues (two primary tumours and ten lymph node or liver
metastases) from all 12 patients were examined by Northern
analysis using subtype-specific riboprobes (Table 2). Expression
of all five somatostatin receptor subtypes was demonstrated in 9
out of 12 tumours. In two midgut carcinoids (cases 1 and 2) sstrl
and sstr3 could not be demonstrated and in one foregut carcinoid
sstr2 was found to be lacking (Figure 1). The hybridization signal
estimated by densitometry was much higher for sstr4 and sstr5
(10- to 100-fold) than for sstrl, sstr2 and sstr3 in both midgut and
foregut carcinoids. The two thymic carcinoids (cases 11 and 12,
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Table 2 Experimental and clinical observations for carcinoid tumours
SSTR expression in vivo
Effect of octreotide in vivo Effect of octreotide in vitro
Case Scintigraphy T/B ratios Biopsy site SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 (reductionof 5-HIAA) (reductionof 5-HT)
1 Positive 153-651 (n=4) Liver - + - + + 31% 71%
2 Positive ND Liver - + - + + ND 45%
3 Positive ND Lymph node + + + + + ND ND
4 Positive ND Lymph node + + + + + 71% ND
5 Positive ND Liver + + + + + 28% 68%
6 Positive ND Liver + + + + + 43% ND
7 Positive 35-151 (n= 3) Liver + + + + + 53% ND
8 Positive ND Liver + + + + + 34% ND
9 Positive ND Liver + + + + + ND 57%
10 Positive 32-210 (n = 8) Lymph node + + + + + ND ND
11 Positive ND Primary + + + + + ND 14%
12 Positive ND Primary + - + + + ND 9%
BON cell line + - + + +
ND = not determined
Mc FC
1 2 3 4 5 6 7 8 9 101112
sstrl
G3PDH
BON
I -4.3kb
I
- 1.4 kb
-8.9 kb
sstr2 w lll i l g-~~~2.4kb
G3PDH 11_ kb
sstr3 4.9 kb
G3PDH 1.4 kb
sstr4
G3PDH ~~I
sstr5
G3PDH
primary tumour tissues) generally expressed lower levels of all
somatostatin receptor subtypes in comparison with metastases
from midgut carcinoids. The BON cell line, derived from a human
pancreatic (foregut) carcinoid, also expressed relatively low levels
of sstrl, sstr3, sstr4 and sstr5, and was devoid of sstr2 (Figure 1).
In each tumour and for each sstr subtype, a single mRNA tran-
script (sstrl, sstr3, sstr4, sstr5) or two transcripts (sstr2) were
detected. The size ofthe mRNA transcripts was in agreement with
those previously reported for human sstr subtypes.
Effect of octreotide treatment
Octreotide treatment was given to all patients with marked reduc-
tion of hormonal symptoms, except for one asymptomatic patient
with a foregut (thymic) carcinoid (case 11). Urinary excretion of
5-HIAA was elevated in all midgut carcinoid patients, and in two
ofthe foregut carcinoid patients (cases 11 and 12). Urinary excre-
tion ofMeImAA was elevated in the gastric carcinoid patient (case
10). Measurements of 5-HIAA before and after initiation of
octreotide treatment were available in six patients. Octreotide
treatment in thesepatients reducedurinary secretion of5-HIAAby
28-71% (Table 2). The effect of octreotide on isolated tumour
cells was studied in primary cultures of four midgut carcinoids
(cases 1, 2, 5 and 9) and two foregut (thymic) carcinoids (case 11
and 12). Incubation ofmidgut tumours with octreotide (10 ,UM) for
7-12 days significantly reducedthe spontaneous secretion of5-HT
and 5-HIAA from tumour cells by 45-71% and 41-94% respec-
tively (Table 3). Incubation of thymic carcinoid tumours with
octreotide (10gM) for 8 days failed to reduce the secretion of 5-
HT to any significant degree, whereas the secretion of 5-HIAA
was reduced by 21%. Octreotide treatmentofBON cells for4 days
increased the secretion of5-HT by 27% but reduced the secretion
of5-HIAA by 54%.
-4.7kb
-1.4 kb
-4.0kb
-1.4kb
Figure 1 Northern analysis of somatostatin receptor expression in human
carcinoid tumours with positive octreotide scintigraphy. Nine midgut
carcinoids (lanes 1-9) and three foregut carcinoids (lanes 10-12) as well as
the pancreatic carcinoid cell line BON (lane 13) were studied by subtype
specific cRNA probes. A majority of the tumours (9 out of 12) expressed all
five sstr subtypes. However, sstr2 could not be detected in one foregut
carcinoid and in the BON cell line. The size of mRNA transcripts is indicated
to the right. Membranes were rehybridized with G3PDH to check the amount
of RNA transferred to the membranes
DISCUSSION
All the carcinoid tumours examined expressed somatostatin recep-
tors as visualized by [11ln]DTPA-D-Phel-octreotide scintigraphy.
This finding was corroborated by high T/B values in three patients,
in whom measurements of "'In activity concentrations were
performed. This is in agreement with our previous reports on
larger series of neuroendocrine tumours demonstrating high T/B
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Table 3 Effect of octreotide on tryptamine secretion from carcinoid tumours in primary culture
5-HT (nmol I-i) Per cent reduction 5-HIAA (nmol 1-') Per cent reduction
Midgut carcinoids
Case 1
Control (n = 8) 454.1 ± 18.0 2464 ± 124
Octreotide (n = 8) 130.2 ± 5.8 71 P< 0.001 151.9 ± 7.2 94 P< 0.001
(10gM, 12 days)
Case 2
Control (n = 8) 826.9 ± 48.6 608.0 + 48.3
Octreotide (n = 8) 452.5 ± 10.5 45, P< 0.001 359.6 ± 16.8 41, P < 0.001
(10gM, 7 days)
Case 5
Control (n = 8) 832.9 ± 53.1 2616.2 ± 202.8
Octreotide (n = 8) 263.2 ± 16.8 68, P< 0.0001 472.2 ± 34.3 82, P< 0.0001
(10 gM, 12 days)
Case 9
Control (n = 8) 4,963 ± 256 10518 ± 375
Octreotide (n = 8) 2,116 ± 99 57, P< 0.001 2279 ± 205 78, P< 0.001
(10gM, 12 days)
Foregut carcinoids
Case 11
Control (n = 7) 431.3 ± 23.0 5438 ± 319
Octreotide (n = 8) 369.1 ± 21.8 14, NS 4300 + 269 21, P < 0.02
(10gM, 8 days)
Case 12
Control (n = 8) 93.6 ± 3.2 ND
Octreotide (n = 8) 85.2 ± 10.4 9, NS ND
(10 gM, 8 days)
BON
Control (n = 8) 404.0 ± 16.5 440.8+ 10.5
Octreotide (n = 8) 512.6 ± 12.0 -27a, P < 0.0001 202.8 ± 2.4 54%, P< 0.0001
(10 gm, 4 days)
NS, not significant; ND, not detectable; a - indicates an increase.
ratios in carcinoid tumours compared with other neuroendocrine
tumours, for example medullary thyroid carcinoma (Forssell-
Aronsson et al, 1995; Wangberg et al, 1996; Ahlman et al, 1997;
Tisell et al, 1997). In general, the T/B ratios seemed to be some-
what lower in primary tumours and lymph node metastases than in
liver metastases. Northern blot analysis in these patients was
performed on metastatic tumour material showing the expression
ofall receptor subtypes in two tumours and the expression ofsstr2,
4 and 5 in one tumour. Nevertheless, liver metastases from the last
tumour had the highest T/B ratios and tumour cells also had a
marked antisecretory response to octreotide. These findings
further indicate that "'IIn-labelled octreotide can be used for radia-
tion therapy of disseminated carcinoid disease provided that "'In
is internalized into the tumour cells, as recently demonstrated
(Andersson et al, 1997). Phase I radiation therapy studies on
patients with disseminated neuroendocrine tumours have demon-
strated effects of "'In-labelled octreotide on hormonal symptoms
and biochemical markers as well as on tumour size (Fjalling et al,
1996; Krenning et al, 1996).
For the first time, we have examined the expression of somato-
statin receptor subtypes in a series ofhuman carcinoid tumours by
Northern analysis and subtype-specific riboprobes. This analysis
combines high sensitivity and specificity and allows semiquantita-
tive estimation of receptor expression. Using this method, all five
somatostatin receptor subtypes could be demonstrated in amajority
of carcinoid tumours, both of foregut and of midgut origin,
although the strongesthybridization signals were observed for sstr4
and 5. Our data confirm the expression of sstr2 in all scintigraphi-
cally positive carcinoid tumours except for one tumour. In addition,
expression of multiple somatostatin receptor subtypes including a
high expression of sstr4 and sstr5 was demonstrated in carcinoid
tumours. This is at a variance with previous studies, in which only
sstr2 could be regularly demonstrated by RT-PCR in scintigraphi-
cally positive neuroendocrine tumours (John et al, 1996). One, less
likely, explanation for this discrepancy is the difference in methods
used to demonstrate sstr subtypes. Another, more likely, explana-
tion for the different results is differences in the tumour material
studied. In the present study, we have primarily investigated a
group of metastasizing ileal carcinoids that express all five sstr
subtypes. Other endocrine tumours, including foregut carcinoids,
medullary and papillary thyroid carcinoma have a different pattern
ofsstrexpression as determined by Northern blotting, often lacking
one or several sstr subtypes (Ahlman et al, 1997; Tisell et al, 1997).
In view of these findings and the pharmacological profile of
octreotide, one may assume that both sstr2 and sstr5 are
responsible for the positive tumour imaging and high "'IIn activity
concentrations observed in carcinoid tumours using octreotide
scintigraphy.
The secretory response of carcinoid tumours to somatostatin
receptor stimulation was studied both in the clinical situation and
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in cultured tumour cells. Patients treated with octreotide
responded with marked reduction of hormonal symptoms as well
as reduction of tumour markers (urinary 5-HIAA excretion),
which indicates an inhibitory effect of somatostatin receptors on
secretory processes in carcinoid tumours. In vitro experiments on
cultured tumour cells confirmed that octreotide exerts a direct
inhibitory effect on hormone secretion from carcinoid tumour
cells. Both 5-HT and 5-HIAA concentrations in culture media
were significantly reduced, suggesting a decrease in both hormone
synthesis, secretion and metabolism after octreotide treatment.
Under the experimental conditions studied octreotide does not
appear to have an antiproliferative effect on tumour cells
(Wangberg et al, 1991; Nilsson et al, 1992). The reduction of5-HT
and 5-HIAA levels observed after octreotide thus appears to be a
highly specific effect of somatostatin receptor activation. The
exact mechanisms by which octreotide inhibits hormone secretion
in carcinoid tumours is not known, but it is noteworthy that
octreotide was more effective in reducing hormone secretion from
midgut carcinoids than from foregut carcinoids, despite a similar
expression of somatostatin receptor subtypes. This difference in
response to octreotide may reflect different absolute or relative
expression of somatostatin receptor subtypes in tumours, but may
also be due to different mechanisms for receptor coupling and
intracellular messenger systems. Further studies, using subtype-
specific agonists or antagonists, are necessary to elucidate the
exact role of each somatostatin receptor subtype in the control of
hormone secretion and growth ofcarcinoid tumours.
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